ID   BXdmg1
AC   CVCL_F4BV
RX   PubMed=35300150;
CC   Characteristics: Displays H3F3A (Histone H3.3) K27M mutation. Retains wild-type IDH1, IDH2 and HIST1H3B. EGFR is not amplified.
CC   Characteristics: Shows ATRX and P53 expression by immunohistochemistry.
CC   Characteristics: Displays adherent growth.
CC   Karyotypic information: No 1p36 or 19q13 deletion.
CC   Sequence variation: Mutation; HGNC; HGNC:4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=35300150).
CC   Miscellaneous: Sex of donor and karyotypic information from personal communication of Hagedorn, Martin.
CC   Derived from site: In situ; Brain, midline region; UBERON=UBERON_0000955.
DI   NCIt; C129309; Diffuse Midline Glioma, H3 K27M-Mutant
DI   ORDO; Orphanet_723358; Diffuse midline glioma, H3 K27-altered
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 25-06-26; Last updated: 25-06-26; Version: 1
//
RX   PubMed=35300150; DOI=10.1093/noajnl/vdac018; PMCID=PMC8923007;
RA   Rahal, Farah
RA   Capdevielle, Caroline
RA   Rousseau, Benoit
RA   Izotte, Julien
RA   Dupuy, Jean-William
RA   Cappellen, David
RA   Chotard, Guillaume
RA   Menard, Melissa
RA   Charpentier, Justine
RA   Jecko, Vincent
RA   Caumont, Charline
RA   Gimbert, Edouard
RA   Grosset, Christophe F.
RA   Hagedorn, Martin
RT   "An EZH2 blocker sensitizes histone mutated diffuse midline glioma to
RT   cholesterol metabolism inhibitors through an off-target effect.";
RL   Neurooncol. Adv. 4:vdac018.1-vdac018.13(2022).
//